Cerebrovascular dysfunction is a significant contributor to Alzheimer’s disease (AD) progression. AD mouse models show altered capillary morphology, density, and diminished blood flow in areas of tau and beta-amyloid accumulation. The purpose of this study was to examine alterations in vascular structure and their contributions to perfusion deficits in the hippocampus in AD and mild cognitive impairment (MCI). Seven individuals with AD and MCI (1 AD/6 MCI), nine cognitively intact older healthy adults, and seven younger healthy adults underwent pseudo-continuous arterial spin labeling (PCASL) and gradient-echo/spin-echo (GESE) dynamic susceptibility contrast (DSC) MRI. Cerebral blood flow (CBF), cerebral blood volume, relative vessel size index (rVSI), and mean vessel density were calculated from model fitting. Lower CBF from PCASL and SE DSC MRI was observed in the hippocampus of AD/MCI group. rVSI in the hippocampus of the AD/MCI group was larger than that of the two healthy groups (FDR-P = 0.02). No difference in vessel density was detected between the groups. We also explored relationship of tau burden from 18F-flortaucipir positron emission tomography and vascular measures from MRI. Tau burden was associated with larger vessel size and lower CBF in the hippocampus. We postulate that larger vessel size may be associated with vascular alterations in AD/MCI.
HymanBTPhelpsCHBeachTG, et al.
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement2012;
8: 1–13.
3.
MontineTJPhelpsCHBeachTG, et al.
National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol2012;
123: 1–11.
4.
BraakHBraakE.Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991;
82: 239–259.
5.
Iturria-MedinaYSoteroRCToussaintPJ, et al.
Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun2016;
7: 11934.
6.
SweeneyMDKislerKMontagneA, et al.
The role of brain vasculature in neurodegenerative disorders. Nat Neurosci2018;
21: 1318–1331.
7.
GovindpaniKMcNamaraLGSmithNR, et al.
Vascular dysfunction in Alzheimer's disease: a prelude to the pathological process or a consequence of it?J Clin Med2019;
8: 20190510. DOI: 10.3390/jcm8050651.
8.
ThalDRGriffinWSde VosRA, et al.
Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol2008;
115: 599–609.
9.
BennettRERobbinsABHuM, et al.
Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A2018;
115: E1289–E1298.
10.
KalariaRNHederaP.Differential degeneration of the cerebral microvasculature in Alzheimer's disease. Neuroreport1995;
6: 477–480.
11.
FarkasELuitenPG.Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol2001;
64: 575–611.
12.
SonntagWELynchCDCooneyPT, et al.
Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology1997;
138: 3515–3520.
13.
AmentaFFerranteFManciniM, et al.
Effect of long term treatment with the dihydropyridine-type calcium channel blocker darodipine (PY 108-068) on the cerebral capillary network in aged rats. Mech Ageing Dev1995;
78: 27–37.
14.
AmentaFCavallottiDDel ValleM, et al.
Age-related changes in brain microanatomy: sensitivity to treatment with the dihydropyridine calcium channel blocker darodipine (PY 108-068). Brain Res Bull1995;
36: 453–460.
15.
BueeLHofPRDelacourteA.Brain microvascular changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci1997;
826: 7–24.
16.
BrownWRThoreCR.Cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol2011;
37: 56–74.
17.
ShiroishiMSCastellazziGBoxermanJL, et al.
Principles of T2*‐weighted dynamic susceptibility contrast MRI technique in brain tumor imaging. J Magn Reson Imaging2015;
41: 296–313.
18.
NielsenRBEgefjordLAngleysH, et al.
Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease. Alzheimers Dement2017;
13: 1143–1153.
19.
EskildsenSFGyldenstedLNagenthirajaK, et al.
Increased cortical capillary transit time heterogeneity in Alzheimer's disease: a DSC-MRI perfusion study. Neurobiol Aging2017;
50: 107–118.
20.
PetcharunpaisanSRamalhoJCastilloM.Arterial spin labeling in neuroimaging. World J Radiol2010;
2: 384–398.
21.
ChenWSongXBeyeaS, et al.
Advances in perfusion magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement2011;
7: 185–196.
22.
ZhangHWangYLyuD, et al.
Cerebral blood flow in mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. Ageing Res Rev2021;
71: 101450.
23.
YablonskiyDAHaackeEM.Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med1994;
32: 749–763.
24.
KiselevVGStreckerRZiyehS, et al.
Vessel size imaging in humans. Magn Reson Med2005;
53: 553–563.
25.
ChakhoyanAYaoJLeuK, et al.
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Sci Rep2019;
9: 2846–2848.
26.
GuoHKangHTongH, et al.
Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes. Eur Radiol2019;
29: 1893–1902.
27.
XuCSchmidtWUVillringerK, et al.
Vessel size imaging reveals pathological changes of microvessel density and size in acute ischemia. J Cereb Blood Flow Metab2011;
31: 1687–1695.
28.
StokesAMSkinnerJTQuarlesCC.Assessment of a combined spin-and gradient-echo (SAGE) DSC-MRI method for preclinical neuroimaging. Magn Reson Imaging2014;
32: 1181–1190.
29.
StokesAMQuarlesCC.A simplified spin and gradient echo approach for brain tumor perfusion imaging. Magn Reson Med2016;
75: 356–362.
30.
StokesAMRagunathanSRobisonRK, et al.
Development of a spiral spin‐and gradient‐echo (spiral‐SAGE) approach for improved multi‐parametric dynamic contrast neuroimaging. Magn Reson Med2021;
86: 3082–3095.
31.
ChangSKKimJLeeD, et al.
Mapping of microvascular architecture in the brain of an Alzheimer's disease mouse model using MRI. NMR Biomed2021;
34: e4481.
32.
XuXMengTWenQ, et al.
Dynamic changes in vascular size and density in transgenic mice with Alzheimer’s disease. Aging (Albany NY)2020;
12: 17224–17234.
33.
ChoiH-IRyuC-WKimS, et al.
Changes in microvascular morphology in subcortical vascular dementia: a study of vessel size magnetic resonance imaging. Front Neurol2020;
11: 545450.
34.
GuoX-YKwonHJRheeHY, et al.
Microvascular morphology alteration using relaxation rate change with gadolinium-based magnetic resonance imaging contrast agent in patients with Alzheimer’s disease. Quant Imaging Med Surg2023;
13: 1–16.
35.
BjornerudASorensenAGMouridsenK, et al.
T1-and T* 2-dominant extravasation correction in DSC-MRI: part I – theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab2011;
31: 2041–2053.
36.
PannetierNLemassonBChristenT, et al.
Vessel size index measurements in a rat model of glioma: comparison of the dynamic (Gd) and steady‐state (iron‐oxide) susceptibility contrast MRI approaches. NMR Biomed2012;
25: 218–226.
37.
McKhannGMKnopmanDSChertkowH, et al.
The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011;
7: 263–269.
38.
HughesCPBergLDanzigerW, et al.
A new clinical scale for the staging of dementia. Br J Psychiatry1982;
140: 566–572.
39.
MorrisJCWeintraubSChuiHC, et al.
The uniform data set (UDS): clinical and cognitive variables and descriptive data from Alzheimer disease centers. Alzheimer Dis Assoc Disord2006;
20: 210–216.
40.
O'BryantSEWaringSCCullumCM, et al.
Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol2008;
65: 1091–1095.
41.
NasreddineZSPhillipsNABédirianV, et al.
The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005;
53: 695–699.
42.
ManhardMKBilgicBLiaoC, et al.
Accelerated whole‐brain perfusion imaging using a simultaneous multislice spin‐echo and gradient‐echo sequence with joint virtual coil reconstruction. Magn Reson Med2019;
82: 973–983.
43.
BryantAGManhardMKSalatDH, et al.
Heterogeneity of tau deposition and microvascular involvement in MCI and AD. Curr Alzheimer Res2021;
18: 711–720.
44.
JohnsonKASchultzABetenskyRA, et al.
Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol2016;
79: 110–119.
45.
JohnsonKAGregasMBeckerJA, et al.
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol2007;
62: 229–234.
46.
Izquierdo-GarciaDHansenAEFörsterS, et al.
An SPM8-based approach for attenuation correction combining segmentation and nonrigid template formation: application to simultaneous PET/MR brain imaging. J Nucl Med2014;
55: 1825–1830.
47.
HansenMBTietzeAKalpathy‐CramerJ, et al.
Reliable estimation of microvascular flow patterns in patients with disrupted blood–brain barrier using dynamic susceptibility contrast MRI. J Magn Reson Imaging2017;
46: 537–549.
BuxtonRBFrankLRWongEC, et al.
A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med1998;
40: 383–396.
50.
AlsopDCDetreJAGolayX, et al.
Recommended implementation of arterial spin‐labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European Consortium for ASL in dementia. Magn Reson Med2015;
73: 102–116.
51.
AnderssonJLSotiropoulosSN.An integrated approach to correction for off-resonance effects and subject movement in diffusion MR imaging. Neuroimage2016;
125: 1063–1078.
52.
BoxermanJSchmaindaKWeisskoffR.Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Am J Neuroradiol2006;
27: 859–867.
53.
EmblemKEMouridsenKBjornerudA, et al.
Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med2013;
19: 1178–1183.
54.
HsuYYYangWSLimKE, et al.
Vessel size imaging using dual contrast agent injections. J Magn Reson Imaging2009;
30: 1078–1084.
55.
KimMParkJEmblemK, et al.
Vessel type determined by vessel architectural imaging improves differentiation between early tumor progression and pseudoprogression in glioblastoma. Am J Neuroradiol2021;
42: 663–670.
56.
TroprèsIPannetierNGrandS, et al.
Imaging the microvessel caliber and density: principles and applications of microvascular MRI. Magn Reson Med2015;
73: 325–341.
57.
LoganJFowlerJSVolkowND, et al.
Graphical analysis of reversible radioligand binding from time – activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab1990;
10: 740–747.
58.
LoprestiBJKlunkWEMathisCA, et al.
Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med2005;
46: 1959–1972.
59.
MintunMLarossaGShelineY, et al.
11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology2006;
67: 446–452.
60.
GompertsSRentzDMoranE, et al.
Imaging amyloid deposition in Lewy body diseases. Neurology2008;
71: 903–910.
61.
AlbrechtDIsenbergALStradfordJ, et al.
Associations between vascular function and tau PET are associated with global cognition and amyloid. J Neurosci2020;
40: 8573–8586.
62.
BaloyannisSJBaloyannisIS.The vascular factor in Alzheimer's disease: a study in Golgi technique and electron microscopy. J Neurol Sci2012;
322: 117–121.
63.
BryantAGLiZJayakumarR, et al.
Endothelial cells are heterogeneous in different brain regions and are dramatically altered in Alzheimer's disease. bioRxiv2023;
2023: 2002. 2016.528825.
64.
BirdCMBurgessN.The hippocampus and memory: insights from spatial processing. Nat Rev Neurosci2008;
9: 182–194.
65.
FrisoniGBFoxNCJackCRJr, et al.
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol2010;
6: 67–77.
66.
DeTureMADicksonDW.The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener2019;
14: 32–18.
67.
SteinmanJSunH-SFengZ-P.Microvascular alterations in Alzheimer's disease. Front Cell Neurosci2020;
14: 618986.
68.
BaekKBennettRHymanB, et al. MRI assessment of vascular disruption in tau pathology animal model (rTg4510 mouse) of Alzheimer disease. 2020 International Society of Magnetic Resonance in Medicine Virtual Conference & Exhibition 2020, 1941.
69.
GuoYLiXZhangM, et al.
Age‑and brain region‑associated alterations of cerebral blood flow in early Alzheimer's disease assessed in AβPPSWE/PS1ΔE9 transgenic mice using arterial spin labeling. Mol Med Rep2019;
19: 3045–3052.
70.
PathakAPWardBDSchmaindaKM.A novel technique for modeling susceptibility-based contrast mechanisms for arbitrary microvascular geometries: the finite perturber method. Neuroimage2008;
40: 1130–1143.
71.
HooijmansCRGravenCDederenPJ, et al.
Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res2007;
1181: 93–103.
72.
CaoYXuHZhuY, et al.
ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology. PLoS Biol2019;
17: e3000313.
73.
ParisDPatelNDelleDonneA, et al.
Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett2004;
366: 80–85.
74.
QiuLNgGTanEK, et al.
Chronic cerebral hypoperfusion enhances tau hyperphosphorylation and reduces autophagy in Alzheimer’s disease mice. Sci Rep2016;
6: 23964–23969.
75.
ShimadaTShindoAMatsuyamaH, et al.
Chronic cerebral hypoperfusion upregulates leptin receptor expression in astrocytes and tau phosphorylation in tau transgenic mice. Neurosci Lett2019;
704: 133–140.
76.
BryantAGHuMCarlyleBC, et al.
Cerebrovascular senescence is associated with tau pathology in Alzheimer's disease. Front Neurol2020;
11: 575953.
77.
FarrarCTKamounWSLeyCD, et al.
In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model. Neuro Oncol2010;
12: 341–350.
78.
KarbeHKerteszADavisJ, et al.
Quantification of functional deficit in Alzheimer's disease using a computer-assisted mapping program for 99m Tc-HMPAO SPECT. Neuroradiology1994;
36: 1–6.
79.
Lacalle-AuriolesMAleman-GomezYGuzman-De-VilloriaJA, et al.
Is the cerebellum the optimal reference region for intensity normalization of perfusion MR studies in early Alzheimer’s disease?PLoS One2013;
8: e81548.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
